Program
Phenobarbital
Also written as “Phenobarbital Sodium Injection” and “Sezaby”.
Its studies are mostly in Seizures · Epilepsy, led by 4 companies.
Drug pagePhenobarbital: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hikma Pharmaceuticalsits history only | 10 open or running | phase 3since Jan 20, 2011 | Jan 20, 2011 | none ahead |
| NEMA Research | 10 open or running | phase 3since Mar 23, 2020 | Mar 23, 2020 | none ahead |
| PharPoint Researchits history only | 10 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| Sun Pharmaceutical Industriesits history only | 11 open or running | phase 4since Oct 13, 2026 | Oct 13, 2026 | Mar 2028phase 4 · NCT07923734 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of NEMA Research only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 23, 2020First study: phase 3 study in Epilepsy, Benign NeonatalFirst studyNCT04320940 · 4 enrolled · United States, Jordan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study NEMA Research leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04320940Epilepsy, Benign Neonatal · United States, Jordan | 3 | Terminated | Feb 1, 2023 | 4 |
How it is read
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.